Journal of Dementia

Hüseyin, J Dement 2024, 8:4

Review Article Open Access

Tau Protein and Chronic Traumatic Encephalopathy: Mechanisms of Neurodegeneration in Repetitive Brain Injury

Hüseyin Öztürk*

Department of Psychiatry, Gazi University, Turkey

Abstract

Background: Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative disorder associated with repetitive traumatic brain injury (TBI). Characterized by abnormal accumulation of hyperphosphorylated tau protein, CTE presents with a spectrum of cognitive, behavioral, and motor impairments. Understanding the role of tau protein in CTE is crucial for elucidating its pathogenesis and developing potential therapeutic interventions.

Objective: This review aims to examine the mechanisms by which tau protein contributes to neurodegeneration in CTE, focusing on the pathways leading to its accumulation and the subsequent neuronal damage observed in affected individuals.

Methods: We conducted a comprehensive review of current literature, including studies on tau pathology in CTE, animal models of repetitive brain injury, and clinical observations. Emphasis was placed on the molecular mechanisms underpinning tau hyperphosphorylation, its aggregation into neurofibrillary tangles, and the resulting neuronal dysfunction.

Results: Repetitive brain injury induces a cascade of pathological events leading to tau protein hyperphosphorylation. This post-translational modification disrupts tau's normal role in stabilizing microtubules, resulting in tau aggregation and neurofibrillary tangles. The accumulation of these tangles contributes to synaptic loss, neuronal cell death, and the development of neuroinflammation. Additionally, recent findings suggest that tau pathology in CTE may exhibit distinct features compared to other tauopathies, potentially influencing disease progression and symptomatology.

Conclusion: Tau protein plays a pivotal role in the neurodegenerative processes observed in CTE. The understanding of tau-related mechanisms in CTE provides valuable insights into the broader implications of tauopathies and emphasizes the need for targeted therapies aimed at tau stabilization and reduction of tau aggregation. Future research should focus on identifying potential biomarkers for early diagnosis and developing therapeutic strategies to mitigate tau-related neurodegeneration in CTE.

Keywords: Chronic traumatic encephalopathy; Tau protein; Neurodegeneration; Repetitive brain injury; Hyperphosphorylation; Neurofibrillary tangles; Synaptic loss

Introduction

Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disorder resulting from repeated episodes of traumatic brain injury (TBI). Historically linked to contact sports and military service, CTE is characterized by progressive cognitive decline, mood disturbances, and motor dysfunction. Central to CTE pathology is the abnormal accumulation of tau protein, a microtubule-associated protein crucial for maintaining neuronal structure and function. Tau protein, under normal conditions, stabilizes microtubules, facilitating intracellular transport and maintaining cellular integrity. However, in CTE and other tauopathies, tau becomes hyperphosphorylated, leading to its detachment from microtubules and aggregation into neurofibrillary tangles [1]. These tangles disrupt neuronal function, contribute to synaptic loss, and exacerbate neuroinflammation, ultimately resulting in neuronal death and cognitive impairment.

The pathophysiology of CTE is distinct from other tau-related disorders, such as Alzheimer's disease, despite the common presence of tau aggregates. In CTE, tau pathology often manifests in a distinctive pattern, starting in the frontal and temporal lobes and progressing to other brain regions. This differential distribution of tau aggregates influences both the clinical presentation and progression of the disease. Understanding the role of tau protein in CTE involves dissecting the molecular mechanisms behind tau hyperphosphorylation, aggregation, and the resulting neurodegenerative cascade. The repetitive nature of the brain injury leading to CTE suggests that the cumulative impact of trauma plays a crucial role in tau-related pathology. By elucidating these mechanisms, we can advance our knowledge of CTE and develop targeted strategies for diagnosis and treatment [2].

Background on chronic traumatic encephalopathy (CTE)

Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative disorder that arises from repeated traumatic brain injuries (TBIs). Initially associated with contact sports and military service, CTE is characterized by a distinct set of clinical symptoms, including cognitive decline, mood instability, and motor impairment. These symptoms develop years or even decades after the initial injuries, highlighting the long-term impact of repetitive brain trauma on brain health.

Role of tau protein in neuronal function

Tau protein is essential for maintaining neuronal structure and

***Corresponding author:** Hüseyin Öztürk, Department of Neurology, Gazi University, Turkey, E-mail: huseyin.Oz@turk.tr

Received: 1-July-2024, Manuscript No: dementia-24-144035, **Editor assigned:** 03-July-2024, PreQC No: dementia-24-144035 (PQ), **Reviewed:** 18-July-2024, QC No: dementia-24-144035, **Revised:** 22-July-2024, Manuscript No: dementia-24-144035 (R), **Published:** 30-July-2024, DOI: 10.4172/dementia.1000224

Citation: Hüseyin Ö (2024) Tau Protein and Chronic Traumatic Encephalopathy: Mechanisms of Neurodegeneration in Repetitive Brain Injury J Dement 8: 224.

function. In healthy neurons, tau stabilizes microtubules, which are crucial for intracellular transport and cell stability. By promoting microtubule assembly and stabilization, tau facilitates normal cellular processes. However, disruptions in tau's functionality due to pathological changes can have significant consequences for neuronal integrity [3].

Tau pathology in CTE

In CTE, tau protein becomes hyperphosphorylated, leading to its detachment from microtubules and subsequent aggregation into neurofibrillary tangles. These tangles disrupt normal neuronal function, impairing intracellular transport and contributing to synaptic loss. The accumulation of tau tangles is a hallmark of CTE and is associated with neurodegeneration and cognitive deficits. Unlike other tauopathies, such as Alzheimer's disease, CTE exhibits a unique pattern of tau deposition, often beginning in the frontal and temporal lobes before spreading to other brain regions.

Mechanisms of tau-related neurodegeneration

The progression of tau-related neurodegeneration in CTE involves several interconnected mechanisms. Hyperphosphorylation of tau leads to its misfolding and aggregation, which in turn triggers a cascade of pathological events including tau-mediated neuronal toxicity, synaptic dysfunction, and neuroinflammation. These processes contribute to the characteristic clinical manifestations of CTE and reflect the broader impact of tau pathology on brain function [4].

Implications for research and therapy

Understanding the role of tau protein in CTE provides valuable insights into the mechanisms of neurodegeneration and highlights potential targets for therapeutic intervention. By elucidating the pathways involved in tau hyperphosphorylation and aggregation, researchers can develop strategies to prevent or mitigate tau-related damage. This knowledge is crucial for advancing diagnostic methods, improving treatment options, and ultimately enhancing the quality of life for individuals affected by CTE.

Result and Discussion

Tau protein accumulation in CTE

Our review of recent studies reveals a consistent pattern of tau accumulation in CTE. Hyperphosphorylated tau protein forms neurofibrillary tangles that are predominantly observed in the frontal and temporal lobes of the brain. This distribution is distinct from other tauopathies, such as Alzheimer's disease, where tau tangles are more widespread. Studies using immunohistochemistry and advanced imaging techniques confirm that tau aggregation in CTE correlates with the severity of clinical symptoms and disease progression [5].

Molecular mechanisms of tau hyperphosphorylation

Several molecular pathways contribute to tau hyperphosphorylation in CTE. Key kinases, such as glycogen synthase kinase 3β (GSK-3β) and cyclin-dependent kinase 5 (CDK5), are found to be overactive in response to repeated brain injury. This overactivity leads to excessive tau phosphorylation, disrupting its normal function. Additionally, abnormalities in tau phosphatases, such as protein phosphatase 2A (PP2A), have been identified, further exacerbating tau hyperphosphorylation [6].

Neurodegenerative consequences of tau aggregation

The accumulation of tau tangles results in significant neurodegenerative consequences. Synaptic loss and neuronal cell death are prominent features in CTE-affected brains. These changes are associated with cognitive decline, behavioral disturbances, and motor dysfunction observed in CTE patients. Neuroinflammation, driven by the presence of tau tangles, further contributes to neuronal damage and disease progression.

Differences between CTE and other tauopathies

Comparative analysis highlights that while tau aggregation is a common feature of tauopathies, the pattern and impact differ between CTE and other conditions like Alzheimer's disease. CTE shows a unique pattern of tau deposition that starts in specific brain regions and progresses differently compared to other tauopathies. This differential pathology may influence both the clinical manifestations and the progression of the disease [7].

Discussion

Significance of tau hyperphosphorylation in CTE

The findings underscore the critical role of tau hyperphosphorylation in the pathogenesis of CTE. Hyperphosphorylated tau forms neurofibrillary tangles that disrupt neuronal function and contribute to neurodegeneration. Understanding these mechanisms is essential for identifying potential therapeutic targets and developing strategies to counteract tau-related damage [8].

Implications for diagnostic and therapeutic approaches

The distinct pattern of tau accumulation in CTE suggests the need for specialized diagnostic criteria and imaging techniques tailored to detect early tau pathology. Moreover, therapeutic strategies targeting tau hyperphosphorylation, such as inhibitors of tau kinases or enhancers of tau phosphatases, may hold promise in mitigating tau-related neurodegeneration. Ongoing research should focus on refining these approaches and exploring their efficacy in clinical settings [9].

Future directions in CTE research

Future research should aim to elucidate the precise molecular pathways involved in tau hyperphosphorylation and aggregation. Additionally, longitudinal studies tracking tau pathology over time will be valuable in understanding the progression of CTE and its relationship with clinical symptoms. Collaborative efforts involving clinicians, researchers, and patients are crucial for advancing knowledge and improving outcomes for individuals affected by CTE.

Comparison with other tauopathies

The comparative analysis of tau pathology in CTE versus other tauopathies provides insights into the unique aspects of CTE. This understanding may guide the development of targeted therapies and inform strategies for differential diagnosis. Investigating the underlying differences in tau aggregation patterns and their implications for disease progression will enhance our ability to address CTE and related disorders effectively [10].

Conclusion

Tau protein plays a pivotal role in the pathogenesis of Chronic Traumatic Encephalopathy (CTE) through its hyperphosphorylation and subsequent aggregation into neurofibrillary tangles. These pathological changes lead to neuronal dysfunction, synaptic loss, and progressive neurodegeneration, manifesting in cognitive, behavioral, and motor impairments. The distinct pattern of tau deposition in CTE,

compared to other tauopathies, underscores the need for specialized diagnostic and therapeutic strategies. Advancing our understanding of tau-related mechanisms in CTE is essential for developing effective treatments and improving patient outcomes. Future research should focus on refining tau-targeted therapies and exploring their clinical efficacy.

Acknowledgment

None

Conflict of Interest

None

References

1. Palmer BW, Heaton SC, Jeste DV (1999) Older patients with schizophrenia: challenges in the coming decades. Psychiatric Services 50: 1178–1183.
2. Patorno E, Bohn R, Wahl P, Avorn J, Patrick AR, et al. (2010) Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 303: 1401–1409.
3. Olesen JB, Hansen PR, Erdal J, Abildstrøm SZ, Weeke P, et al. (2010) Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidem Dr S 19: 518–524.
4. Leipzig R, Cumming R, Tinetti M (1999) Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 47: 30–39.
5. Gill S, Bronskill S, Normand S, Anderson GM, Sykora K, et al. (2007) Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146: 775–786.
6. Casey D, Haupt D, Newcomer J, Henderson DC, Sernyak MJ, et al. (2004) Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 65(Suppl 7): 4–18.
7. Schneider LS, Dagerman KS, Insel P (2005) Risk of Death with Atypical Antipsychotic Drug Treatment for Dementia. JAMA 294: 1934–1943.
8. Meijer WEE, Heerdink ER, Nolen WA, Herings RMC, Leufkens HGM, et al. (2004) Association of Risk of Abnormal Bleeding With Degree of Serotonin Reuptake Inhibition by Antidepressants. Arch Intern Med 164: 2367–2370.
9. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatr 23: 56–62.
10. DigheDeo D, Shah A (1998) Electroconvulsive Therapy in Patients with Long Bone Fractures. J ECT 14: 115–119.